Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | US

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Renascience Inc. Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.	Japan	4889
Rentracks CO.,LTD. A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.	Japan	6045
Replimune Group, Inc. Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.	United States of America	REPL
ReproCELL Incorporated Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.	Japan	4978
RESEARCH FRONTIERS INC Develops and licenses smart glass tech for instant light, UV, and heat control.	United States of America	REFR
Resolute Holdings Management, Inc. Asset management firm acquiring and operationally enhancing companies for long-term growth.	United States of America	RHLD
RIBOMIC Inc. Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.	Japan	4591
Rise Consulting Group, Inc. Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.	Japan	9168
ROQUEFORT THERAPEUTICS PLC Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.	United Kingdom	ROQ
ROSS GROUP PLC A holding company in liquidation, formerly providing supply chain management & technology solutions.	United Kingdom	RGP